20231009-长城国瑞证券-医药生物行业双周报2023年第19期总第93期_看好行业回升_关注创新药及头部CXO_20页_1mb

Summary Of 2023 Q3 Pharmaceutical And Biotech Industry

This document summarizes the key points from the pharmaceutical and biotech industry double-weekly report dated September 18 to September 28, 2023. The main sections include industry performance, valuation, policy updates, company events, investment recommendations, and risks.

Report Overview: The industry has shown strong growth with a 299% increase in its index, outperforming the CSI 300 Index by 0.52%. Sub-industries vary, with some experiencing high gains while others saw declines.

Industry Performance:
Pharmaceutical R&D outsourcing and vaccines led the gains with 765% and 413%涨幅 respectively, highlighting innovation and clinical value. In contrast, offline pharmacies and medical equipment faced losses of 0.47% and 0.10%.

Valuation:
The industry's Price-to-Earnings (PE) ratio, using TTM and excluding negatives, rose to 26.79x from 26.10x, below one standard deviation. Valuations are uneven across sub-sectors, with healthcare services averaging around 27.07x PE.

Policy And Regulatory Updates:
Key policies from NMPA and CDE stress innovation and clinical utility, such as no new applications for generic drugs if the first passes evaluation. Events like the release of similar documents indicate a focus on efficiency and patient needs.

Company Highlights:
Notable events include drug approvals (e.g., Niramikitabine domestically) and corporate actions like acquisitions and equity changes, driven by synergy and strategic moves.

Investment Recommendations:
The sector is expected to rebound due to upcoming ESMO meetings and performance disclosures. Recommendations focus on innovative drugs and leading Contract Research Organizations (CROs).

Risk Factors:
Potential risks include policy uncertainty, public health concerns, and slower-than-anticipated developments, which could impact performance.

Clearly, these elements reflect a recovery in the industry, supported by supportive regulatory frameworks and emerging innovations. Continuous monitoring is advised for accurate investment timing.